¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"product surveillance, postmarketing"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® blood product ÇÑ±Û Ç÷¾×Á¦Á¦
¼³¸í   
  1. »ç¶÷ÀÇ Ç÷¾×À» ¼ººÐº°·Î ºÐ¸®ÇÏ¿©, ±×°ÍÀ» ¿ø·á·Î Á¦Á¶ÇÑ ÀǾàǰ. ¾Ç¼º Á¾¾ç µûÀ§¿¡ ¼öÇ÷Çϴ ÀûÇ÷±¸, ¹éÇ÷º´-ÀÚ»ö¹Ýº´ÀÇ ÃâÇ÷À» ¸Ü°ÔÇϴ Ç÷¼ÒÆÇ, È­»óÀÇ Ä¡·á¿¡ ¾²´Â Ç÷Àå, »êÈÄ ÃâÇ÷À» ¸Ü°Ô Çϴ ¼¶À¯¼Ò¿ø µûÀ§°¡ ÀÖ´Ù. 2. »ç¶÷ÀÇ Ç÷¾×ÇüÀ» °Ë»çÇϴµ¥ ¾²´Â ¾à.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • epidemiological surveillance
    ¿ªÇа¨½Ã
  • immune surveillance
    ¸é¿ª°¨½Ã
  • immunological surveillance
    ¸é¿ª°¨½Ã
  • infection control surveillance
    °¨¿°°ü¸®°¨½Ã
  • post-marketing surveillance
    ½ÃÆÇÈĺÎÀÛ¿ë°¨½Ã
  • surveillance
    °¨½Ã, °¨µ¶
  • assimilation product
    µ¿È­»ý¼º¹°
  • biological product
    »ý¹°ÇÐÀûÁ¦Á¦
  • blood product
    Ç÷¾×Á¦Á¦
  • degradation product
    ºÐÇØ»ê¹°
  • decay product
    ºØ±«»ê¹°
  • end product
    ÃÖÁ¾»ê¹°
  • fibrin degradation product
    ¼¶À¯¼ÒºÐÇØ»ê¹°, ÇǺ기ºÐÇØ»ê¹°
  • intermediate product
    Áß°£»ê¹°
  • leukocyte-depleted blood product
    ¹éÇ÷±¸Á¦°ÅÇ÷¾×Á¦Á¦
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • surveillance
    °¨½Ã
  • product
    »ý¼º¹°, »ê¹°
  • blood product
    Ç÷¾×Á¦Á¦
  • end product
    ÃÖÁ¾»ê¹°
  • fibrinogen degradation products product
    ¼¶À¯¼ÒºÐÇØ»ê¹°
  • fibrinogen degradation products product
    ¼¶À¯¼Ò¿øºÐÇØ»ê¹°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • surveillance data
    °ü¸®Á¤º¸Á¶»çÀÚ·á
  • epidemiological surveillance
    ¿ªÇа¨½Ã,
  • immune surveillance
    ¸é¿ª°¨½Ã
  • immunological surveillance
    ¸é¿ª°¨½Ã
  • infection control surveillance
    °¨¿°°ü¸®°¨½Ã
  • post-marketing surveillance
    ½ÃÆÇÈĺÎÀÛ¿ëÁ¶»ç
  • surveillance
    °¨½Ã
  • surveillance
    ¿ªÇаü¸®Á¤º¸Á¶»ç
  • assimilation product
    µ¿È­»ý»ê¹°
  • biological product
    »ý¹°ÇÐÀûÁ¦Á¦
  • blood product
    Ç÷¾×Á¦Á¦
  • pearson¡¯s product moment correlation
    ÇǾ»ó°ü°è¼ö
  • decay product
    ºØ±«»ê¹°
  • degradation product
    ºÐÇØ»ê¹°
  • end product
    ÃÖÁ¾»ê¹°
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • addition product
    ºÎ°¡»ý¼º¹°(¡­ßæà÷Úª).
  • product costing
    Á¦Ç°°¡°Ý»êÁ¤
  • product of metabolism
    ´ë»ç»ê¹°(ÓÛÞóß§Úª).
  • PMS : post marketing surveillance
    ½ÃÆÇÈÄ ºÎÀÛ¿ëÁ¶»ç.
  • immune surveillance
    ¸é¿ª°¨½Ã
  • immune surveillance
    ¸é¿ª[ÇÐÀû]°¨½Ã±âÀü
  • immunologic surveillance
    ¸é¿ª°¨½Ã(±â±¸).
  • immunological surveillance
    ¸é¿ª°¨½Ã(±â±¸)(ÊÙ˧Ëà˻˴), ¸é¿ªÁ¶»ç.
  • immunological surveillance
    ¸é¿ª°¨½Ã(±â±¸)(¡­ÊøãÊѦϰ), ¸é¿ªÁ¶»ç.
  • infection control surveillance
    °¨¿°°ü¸®°¨½Ã
  • post marketing surveillance
    ½ÃÆÇÈÄ ºÎÀÛ¿ëÁ¶»ç
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • epidemiological surveillance
    ¿ªÇÐÀû °¨½Ã(ËçÌ°ËøË§Ëà), ¿ªÇÐÀû °ü¸®Á¤º¸Á¶ »ç.
  • immune surveillance
    ¸é¿ª[ÇÐÀû]°¨½Ã±âÀü
  • immune surveillance
    ¸é¿ª°¨½Ã
  • immunologic surveillance
    ¸é¿ª°¨½Ã(±â±¸).
  • immunological surveillance
    ¸é¿ª°¨½Ã(±â±¸)(¡­ÊøãÊѦϰ), ¸é¿ªÁ¶»ç.
  • immunological surveillance
    ¸é¿ª°¨½Ã(±â±¸)(ÊÙ˧Ëà˻˴), ¸é¿ªÁ¶»ç.
  • infection control surveillance
    °¨¿°°ü¸®°¨½Ã
  • post marketing surveillance
    ½ÃÆÇÈÄ ºÎÀÛ¿ëÁ¶»ç
  • surveillance
    °ü¸®Á¤º¸Á¶»ç(Ë´ËöËøËÓÌ¡Ë×), °¨½Ã±â±¸(˧Ëà˻˴).
  • surveillance data
    °ü¸®Á¤º¸Á¶»çÀÚ·á
  • addition product
    ºÎ°¡»ý¼º¹°(¡­ßæà÷Úª).
  • assimilation product
    µ¿È­»ý»ê¹°.
  • biological product
    »ý¹°ÇÐÀû Á¦Á¦(¡­ð²ð¥).
  • blood product
    Ç÷¾×Á¦Á¦.
  • by-product
    ºÎ»ê¹°.
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • excretory-secretory product
    ºÐºñ¹è¼³¹°
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • immune surveillance theory
    ¸é¿ª °¨½Ã ÀÌ·Ð(Øóæ¹ÊøãÊ×âÖå)
  • immunological surveillance theory
    ¸é¿ª °¨½Ã ÀÌ·Ð(Øóæ¹ÊøãÊ×âÖå)
  • advanced glycosylation end product
    ÁøÇà ´çÈ­Á¾»ê¹°(òäú¼ÓØûùðûß§Úª)
  • Amadori product
    ¾Æ¸¶µµ¸® »ý¼º¹°(ßæà÷Úª)
  • by-product
    ºÎ»ê¹°(Üùß§Úª)
  • end product
    Á¾»ê¹°(ðûß§Úª)
  • end-product inhibition
    Á¾»ê¹° ÀúÇØ (ðûß§ÚªîÁúª)
  • end product repression
    Á¾»ê¹° ¾ïÁ¦ (ðûß§Úªåäð¤)
  • gene product
    À¯ÀüÀÚ(ë¶îîí­) »ê¹°
  • product
    »ê¹°(ß§Úª)
  • product inhibition
    »ê¹°ÀúÇØ(ß§ÚªîÁúª)
  • solubility product
    ¿ëÇØµµ(éÁú°Óø) °ö
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • dairy product
    ³«µ¿»ê¹°
  • product
    »ê¹°, »ý¼º¹°
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
PMS patient management system; perimenstrual syndrome; periodic movements during sleep; phenazine methos...
FDP fibrin degradation product; fibrinogen degradation product; flexor digitorum profundus; frontodextra...
BCDSP Boston Collaborative Drug Surveillance Program
CDSC Communicable Diseases Surveillance Centre [London]
COMPASS Computerized Online Medicaid Pharmaceutical Analysis and Surveillance System
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ABLES Adult Blood Lead Epidemiology and Surveillance program
BRFSS Behavioral Risk Factor Surveillance System
CDSC Communicable Disease Surveillance Centre
NEISS National Electronic Injury Surveillance System
NNIS National Nosocomial Infection Surveillance
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • epidemiological surveillance
    ¿ªÇÐÀû °¨½Ã
  • biological product
    »ý¹°ÇÐÀû Á¦Á¦
  • blood product
    Ç÷¾× Á¦Á¦
  • by-product
    ºÎ»ê¹°, ºÎ»ý¹°
    Áֻ깰À» »ý»êÇÏ´Â °úÁ¤¿¡¼­ »ý±â´Â ÀÌÂ÷Àû »ê¹°.
  • degradation product
    ºÐÇØ »ê¹°
  • distortion product otoacoustic emission
    º¯Á¶ ÀÌÀ½Ç⠹ݻç
  • inflammatory by-product
    ¿°Áõ ºÎ»ê¹°
  • ionic product
    ÀÌ¿ÂÀû, À̿ »ê¹°
  • metabolic waste product
    ´ë»ç ³ëÆó¹°, ´ë»ç »ê¹°
  • natural product

    natural purification (ÀÚÁ¤ ÀÛ¿ë

    µ¿ÀǾî=self-
  • product
    »ê¹°, »ý¼º¹°
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
product surveillance, postmarketing Surveillance of drugs, devices, appliances, etc., for efficacy or adverse effects, after they have been released for general sale.
(12 Dec 1998)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
cancer, colon: screening and surveillance Colon cancer is both preventable and curable. It is preventable by removing precancerous colon polyps. It is curable if early cancer is surgically removed before cancer spread to other parts of the body. Therefore, if screening and surveillance programs were practiced universally, there would be a major reduction in the incidence and mortality of colon cancer.
(12 Dec 1998)
population surveillance <epidemiology> Ongoing scrutiny of a population (general population, study population, target population, etc.), generally using methods distinguished by their practicability, uniformity, and frequently their rapidity, rather than by complete accuracy.
(12 Dec 1998)
post-marketing surveillance Procedure implemented after a drug has been licensed for public use, designed to provide information on use and on occurrence of side effects, adverse effects, etc.
(05 Mar 2000)
sentinel surveillance Monitoring of rate of occurrence of specific conditions to assess the stability or change in health levels of a population. It is also the study of disease rates in a specific cohort, geographic area, population subgroup, etc. To estimate trends in larger population.
(12 Dec 1998)
surveillance Oversight; watch; inspection; supervision. "That sort of surveillance of which . . . The young have accused the old." (Sir W. Scott)
Origin: F, fr. Surveiller to watch over; sur over + veiller to watch, L. Vigilare. See Sur-, and Vigil.
Source: Websters Dictionary
(01 Mar 1998)
immune surveillance <immunology> The hypothesis that lymphocyte traffic ensures that all or nearly all parts of the vertebrate body are surveyed by visiting lymphocytes in order to detect any altered self material, for example mutant cells.
(18 Nov 1997)
immunological surveillance <immunology> The hypothesis that lymphocyte traffic ensures that all or nearly all parts of the vertebrate body are surveyed by visiting lymphocytes in order to detect any altered self material, for example mutant cells.
(18 Nov 1997)
immunologic surveillance The theory that T-cells monitor cell surfaces and detect structural changes in the plasma membrane and/or surface antigens of virally or neoplastically transformed cells.
(12 Dec 1998)
activation product <radiobiology> The unstable nucleus formed when activation occurs. (See activation above.)
(09 Oct 1997)
by-product <chemistry> A product of a chemical reaction or industrial process which is different from the desired product.
(20 Mar 1998)
by-product material Radioactive material produced by nuclear fission or by neutron irradiation in a nuclear reactor or similar device.
(05 Mar 2000)
gene product The biochemical material, either RNA or protein, resulting from expression of a gene. The amount of gene product is used to measure how active a gene is, abnormal amounts can be correlated with disease-causing alleles.
(09 Oct 1997)
cleavage product A substance resulting from the splitting of a molecule into two or more simpler molecules.
(05 Mar 2000)
product 1. Anything that is produced, whether as the result of generation, growth, labour, or thought, or by the operation of involuntary causes; as, the products of the season, or of the farm; the products of manufactures; the products of the brain. "There are the product Of those ill-mated marriages." (Milton) "These institutions are the products of enthusiasm." (Burke)
2. <mathematics> The number or sum obtained by adding one number or quantity to itself as many times as there are units in another number; the number resulting from the multiplication of two or more numbers; as, the product of the multiplication of 7 by 5 is 35. In general, the result of any kind of multiplication. See the Note under Multiplication.
Synonym: Produce, production, fruit, result, effect, consequence, outcome, work, performance.
Origin: L. Productus, p. Pr. Of producere. See Produce.
Source: Websters Dictionary
(01 Mar 1998)
product, gene The RNA or protein that results from the expression of a gene. The amount of gene product is a measure of the degree of gene activity.
(12 Dec 1998)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Product Surveillance, Postmarketing - »õâ Surveillance of drugs, devices, appliances, etc., for efficacy or adverse effects, after they have been released for general sale.
    Synonyms : Product Surveillance, Post-Marketing, Drug Surveillances, Postmarketing, Evaluation Study, Postmarketing, Post-Marketing Product Surveillance, Post-Marketing Product Surveillances, Postmarketing Drug Surveillance, Postmarketing Drug Surveillances
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • surveillance
    °¨½Ã; °¨µ¶
  • electronic surveillance
    ÀüÀÚ °¨½Ã(Á¤º¸ ¼öÁý)
  • immune surveillance
    IMMUNOLOGICAL SURVEILLANCE
  • surveillance
    °¨½Ã;°¨µ¶;under ~ °¨µ¶À» ¹Þ°í
  • by-product
    ºÎ»ê¹°
  • product
    (º¹¼ö)»ý»ê¹°,¼º°ú
  • end product
    ¿¬¼Ó º¯È­ÀÇ ÃÖÁ¾°á°ú;ÃÖÁ¾ »ý¼º¹°
  • fission product
    Çٺп­ »ý¼º¹°
  • generic product
    »óÇ¥¾øÀÌ ÀϹݸíÀ¸·Î ÆÇ¸ÅµÇ´Â »óǰ
  • gross domestic product
    ±¹³» ÃÑ»÷»ê(GDP)
  • gross national product
    ±¹¹Î ÃÑ»ý»ê D
  • inner product
    ³»Àû
  • national product
    (°æ)(¿¬°£)±¹¹Î»ý»ê(cf.GNP)
  • net domestic product
    ±¹³» ¼ø»ý»ê
  • net national product
    ±¹¹Î¼ø»ý»ê
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á